Bicara Therapeutics Inc. $BCAX Shares Purchased by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. raised its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 49.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 427,885 shares of the company’s stock after buying an additional 142,390 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Bicara Therapeutics were worth $7,963,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in BCAX. Alps Advisors Inc. grew its position in shares of Bicara Therapeutics by 32.5% during the third quarter. Alps Advisors Inc. now owns 87,692 shares of the company’s stock worth $1,632,000 after acquiring an additional 21,510 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $63,000. Profund Advisors LLC increased its holdings in shares of Bicara Therapeutics by 7.2% in the 3rd quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after acquiring an additional 1,140 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Bicara Therapeutics by 15.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock valued at $224,000 after purchasing an additional 1,617 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its position in Bicara Therapeutics by 457.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock valued at $26,000 after purchasing an additional 1,138 shares during the last quarter.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the sale, the chief executive officer directly owned 181,641 shares in the company, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.80% of the company’s stock.

Bicara Therapeutics Stock Performance

Shares of NASDAQ BCAX opened at $10.11 on Friday. Bicara Therapeutics Inc. has a fifty-two week low of $7.87 and a fifty-two week high of $30.99. The firm’s 50-day simple moving average is $17.10 and its 200 day simple moving average is $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, November 9th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.22). On average, sell-side analysts expect that Bicara Therapeutics Inc. will post -3.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research note on Thursday, September 10th. Citigroup restated a “market outperform” rating on shares of Bicara Therapeutics in a research note on Tuesday. The Goldman Sachs Group cut Bicara Therapeutics from a “neutral” rating to a “sell” rating and cut their price target for the company from $20.00 to $8.00 in a report on Friday, October 30th. BMO Capital Markets began coverage on Bicara Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, Morgan Stanley reduced their price objective on Bicara Therapeutics from $41.00 to $30.00 and set an “overweight” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

Key Stories Impacting Bicara Therapeutics

Investors following BCAX have been watching these stories:

• Positive Sentiment: HC Wainwright kept its Buy rating on BCAX and a $36 price target, which could support investor optimism despite the target reduction from $42. HC Wainwright target update
• Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, and BTIG Research issued a pessimistic forecast. These actions may weigh on sentiment; the provided headlines do not specify the revised targets or detailed rationale. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright’s 2027 estimates project continuing quarterly losses, including a full-year loss of $4.63 per share. Expectations of ongoing losses can be a headwind for a clinical-stage biotech, even with the firm’s Buy rating.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.